Tarsus Pharmaceuticals Inc (TARS)
48.14
+1.40
(+3.00%)
USD |
NASDAQ |
Jan 22, 16:00
48.14
0.00 (0.00%)
After-Hours: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.840B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 99.06% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 13.45 |
Price to Book Value | 7.749 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.3019 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Edit
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
URL | https://www.tarsusrx.com |
Investor Relations URL | https://ir.tarsusrx.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Pharmaceuticals |
Next Earnings Release | Feb. 27, 2025 (est.) |
Last Earnings Release | Nov. 13, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
URL | https://www.tarsusrx.com |
Investor Relations URL | https://ir.tarsusrx.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Pharmaceuticals |
Next Earnings Release | Feb. 27, 2025 (est.) |
Last Earnings Release | Nov. 13, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |